🇮🇳IN
Sign In
JE

JENBURPH

NSE

Jenburkt Pharmaceuticals Ltd

₹870.95

-0.45(-0.05%)
FSI

Fundamental Strength Index

computed from the statements below↑ higher is better

Weights come from configuration, not from this page — each pillar links to the section below that explains it.

Income stmtHistory

Profitability

headline ratios

Growth

compounded, from filed annual results

Segment Results

₹ Cr

Working Capital & Efficiency

days · ROCE %

JENBURPH financial summary

For Mar 2026, Jenburkt Pharmaceuticals Ltd reported revenue of ₹169 crore, which grew 11.2% from the previous year. Net profit was ₹35 crore, which grew 9.4% year on year, on an operating margin of 26%. Earnings per share came in at ₹78.72. Annual results are available for 14 financial years, from Mar 2013 to Mar 2026.

Revenue₹169 crore
Net profit₹35 crore
Operating margin26%
EPS₹78.72

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Disclaimer